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Visceral Leishmaniasis (VL) is a tropical disease,
which is caused by parasite Leishmania donovani.
FemalePhlebotomus argentipes (commonly known as
sand fly) which has feasted on a human infected by
Leishmania, transmits the parasite from infected to
the healthy humans. Visceral Leishmaniasis (Kalaazar) is the disease of poverty and generally affects
the poorest of the poor. ,,,
Kala-azar is also known as the Black fever and
Dumdum fever and has been endemic in India since
historical times and Bengal is the oldest known
Kala-azar endemic area in the world. The word
‘kala’ means black and ‘azar’ means fever in Hindi,
the disease gets its name because of the peculiar
darkening of the skin. If left untreated, it can lead
to death in 100% of the patients within two years’
time. The disease-causing organism (parasite) for
the first time was identified by Dr William Leishman
in Calcutta (Dumdum), India and by Dr Charles
Donovan from a patient suffering from prolonged
fever in Madras (Chennai) almost simultaneously
in year 1903. The organism was named after both
of them as ‘Leishmania donovani.’ The transmission
of Kala-azar in Indian sub-continent is restricted
to areas with heavy annual rainfall, mean humidity
above 70%, a temperature range of 15–38°C, with
abundant vegetation, subsoil water and alluvial soil.
The disease is commonly seen in villages where
houses are constructed of mud walls, and cattle and
other livestock are living close to humans.
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The patient infected by Leishmania donovani has
presence of parasite in the organs (spleen, liver and
bone marrow) involved in hematopoiesis and leads
to complaints of fever, loss of weight, weakness
and loss of appetite. Post Kala-azar Dermal
Leishmaniasis (PKDL) is a late sequel, among those
who have received treatment for VL in the past and
patients usually present with painless lesion of skin
that may be macular, papular and/or nodular.
The Directorate of National Vector Borne Disease
Control Program (NVBDCP) recommends the
following treatment modalities for VL and PKDL
cases
•

Visceral Leishmaniasis: (i) Single-dose single
day treatment with Liposomal Amphotericin B
injection (Treatment of choice) or (ii) capsule
Miltefosine (28 days) and injection Amphotericin
B (15 injections on alternate days) or (iii)
combination of Miltefosine and Paramomycin
injection.

•

Post Kala-azar Dermal Leishmaniasis: (i)
Miltefosine: 100mg orally per day for 12 weeks
(Treatment of choice) or (ii) Amphotericin B
deoxycholate: 1mg/kg over four months 60-80
doses, or (iii) Liposomal Amphotericin B: 5mg/
kg per day by infusion two times per week for
three weeks for a total dose of 30mg/kg. Case
management of special conditions like relapse,
HIV-VL co-infection and others will follow
WHO treatment guidelines.

More than 147 million people are at risk of
acquiring VL, in the Southeast Asian region,, WHO
has identified VL as a major public health concern.
With VL having localized geography, humans
being the only host reservoirs, and Sand fly being
the only vector responsible for the transmission;
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the availability of effective tools for its diagnosis
and treatment makes VL amenable to elimination. ,
The Governments of India, Bangladesh and Nepal
signed a tripartite memorandum of understanding
in 2005 for reducing the incidence of VL to less than
one case per 10,000 populations at the block level
through intercountry cooperation and cross-border
collaboration and achieved elimination of VL by
2015.
In 2014, India, Bhutan, Thailand, Nepal and
Bangladesh signed a memorandum of understanding
to eliminate VL from the South East Asia Region of
WHO by 2017.,
As per the WHO, India would achieve the elimination
of VL when the annual incidence of VL declines to
less than one case of VL per 10,000 populations at
the block level in all VL endemic districts.
Kala-Azar is endemic in the state of Bihar, West
Bengal, Jharkhand and districts of Eastern Uttar
Pradesh. In the decade of 1970s, VL had almost
disappeared due to the use of DDT for vector control
under the Malaria Control Program. However, due
to the environmental concerns regarding the use of
DDT for vector control, the use of DDT was stopped
as a result of which there was not only increase in
the cases of Malaria but also of VL. The present
strategy of National Program for Elimination of
VL includes following components
•

Early diagnosis and complete treatment

•

Integrated vector management
Indoor residual spraying (IRS)

•

Advocacy, communication for behavioural
impact and inter-sectoral convergence

•

Capacity building

•

Supervision, monitoring and evaluation.

including

The National Program has made tremendous
progress towards elimination through focused and
data-driven decision-making facilitated by the timely
availability of data for program activities.
With the introduction of rapid diagnostic test kit
(rK39) and treatment with a single dose of liposomal
Ambisome, the national program has accelerated
early diagnosis and complete treatment of VL cases.
2
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The national program has bolstered the vector
control measures through introduction of Synthetic
Pyrethroid and replacement of stir-up pumps
with Hudson pumps for indoor residual spraying.
A threefold decline in the number of VL cases
was recorded from 2013 (13,869) to 2018 (4,380).
By beginning of 2019, among the 633 endemic
blocks endemic for Kala-azar, 91.6% (580) blocks
have achieved the annual incidence required for
elimination. Among the 53 blocks, which continue
to have annual incidence of VL more than 1 case
per 10,000 population at the block level, 35 blocks
are from Bihar, 17 from Jharkhand and 1 from Uttar
Pradesh. The villages from where cases of Kalaazar were reported halved between 2013 and 2018.
The success of the National Kala-Azar Elimination
program can be attributed to the following
1. Enhanced data analytics and data-backed
decision-making process
2. Enhanced monitoring of the program activities
3. Intensification of elimination activities in the
blocks with persistent transmission
4. Enhanced incentive for the patient for completing
treatment
5. Intensification of post-treatment follow-up of
cases for identification of cases of relapse
6. Capacity building of frontline workers for early
identification and referral of suspected cases of
VL and Post-Kala-Azar Dermal Leishmaniasis
(PKDL)
7. Leveraging on the existing national program for
the elimination of Leprosy for confirmation of
diagnosis of PKDL at the level of districts.
8. Integration with the National AIDS Control
Program and the National Tuberculosis Control
Program for mandatory screening of patients
of VL for HIV and Tuberculosis.
Although National VL elimination program has
made impressive progress and the disease has now
been limited to a small number of blocks, there are
still concerns, which need attention. The National
Program for Elimination of Visceral Leishmaniasis
should address the following challenges to sustain
the progress towards elimination-
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Sustaining elimination: The 1970s resurgence of
Kala-azar became evident; when the use of DDT for
Malaria control activities was discontinued owing
to its potential environmental impacts. The global
initiative for elimination of VL has not envisioned
‘elimination’ of the pathogen, which will warrant
low-level transmission to continue. With the
country achieving elimination of VL, it would mean
decline in the number of cases and consequently it
is likely that there would be complacency in the level
of awareness among the health care providers and
decreased availability of resources for diagnosis,
treatment and vector control. Post Kala-azar, dermal
Leishmaniasis and VL cases with HIV co-infection
have demonstrated to serve as reservoirs of
Leishmania parasite and may have a role to play in
sustaining transmission at low levels and facilitating
resurgence of Kala-azar in post-elimination phase.
Hence, it is imperative that surveillance activities are
adjusted to the post-elimination phase to maintain
continued detection of Kala-azar cases.
Improved diagnostic tools: The early case
detection has improved manifold with the
introduction of antibody-based rapid diagnostic test
(RDT) kits (rk16 and rK39) for Kala-azar. These
rapid diagnostic kits are very useful for detecting
cases of visceral leishmaniasis who have acquired
the infection for the first time. These RDT’s are
based on antibody detection; hence even the treated
cases of Leishmania continue to give a false positive
test as the antibodies developed for Leishmania
persist for many years. This inherent problem with
the RDTs makes the identification of cases of reinfection difficult. The clinical features of PKDL are
difficult to differentiate from other skin conditions
like leprosy and fungal infections, hence requiring
an invasive test like slit skin smear or skin biopsy
for confirmation. The invasive tests for confirming
diagnosis of PKDL are not usually present at the
level of primary health centres, therefore, delaying
their diagnosis and treatment. It is essential to
develop a diagnostic test, which is not only more
specific and sensitive for identifying the cases of VL
and PKDL but can be used as a test for cure after
treatment.

Newer drugs: With the introduction of Liposomal
Ambisome, the duration of treatment for VL has
reduced from 28 days to one day. In cases of VL with
HIV co-infection, a higher dose of Ambisome has
been recommended. The treatment of VL cases is
now dependent on a single drug that is manufactured
by one company globally. Relapse of VL is known
to occur in patients treated with Ambisome;
hence it will be prudent to identify other possible
combinations of drugs, which may be used for
treatment of VL cases. Miltefosine is recommended
for the treatment of PKDL and it has to be consumed
daily for 12 consecutive weeks. The long duration
of treatment with Miltefosine is a probable reason
for non-compliance among the patients; hence new
shorter and efficacious treatments’ regimens need to
be explored.
Vector control measures to reduce transmission:
Indoor residual spray for control of sand flies is
critical for reducing the transmission of VL. The
national program for elimination of VL moved from
use of DDT to synthetic pyrethroid as insecticide of
choice. The insecticide needs to be changed based on
the results of insecticide sensitivity tests. Testing
of sand flies for resistance to insecticide needs to
be conducted diligently and data generated should
be used for guiding choice of insecticide for vector
control measures.
Strengthening the surveillance and early
cases’ detection: There has been an impressive
improvement in the early detection of cases of VL
and now lesser numbers of cases are missed from
getting tested for VL. This achievement needs to be
sustained and consolidated, so that all cases of VL
and PKDL are identified and treated at the earliest.
It is expected as the number of cases will decline
the awareness and knowledge about Kala-azar will
fall among the clinicians, front line workers and
the community, therefore it is critical that strategy
should be devised to sustain the level of awareness
among all the stakeholders.
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